Business
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these in
About this update from Akeso, Inc.
[{"type":"text","content":"HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these inclusions, all approved indications for Akeso's five independently commercialized, internally developed drugs are now part of the NRDL.","length":706,"tagName":"p"},{"type":"text","content":"Dr. Yu Xia, Founder, Chairwoman, President, and CEO of Akeso, said: "We are truly delighted to witness that all approved indications of the company's five self-developed innovative drugs have been successfully included in the National Reimbursement Drug List (NRDL). The inclusion of these drugs—which address major tumor diseases with the highest incidence rates in China, such as lung cancer, gastric cancer, cervical cancer, and nasopharyngeal cancer, as well as metabolic and autoimmune disorders like hypercholesterolemia and psoriasis—enables Chinese patients to be among the first in the world to benefit from optimal treatment options. This achievement reduces the financial burden on patients and provides superior alternatives for tackling significant public health challenges. Notably, even prior to their inclusion in the NRDL, these drugs had already gained extensive and profound recognition from hospitals, physicians, and patients in real-world clinical practice, thanks to their breakthrough clinical value. The successful entry of multiple indications of these five products into the NRDL will further enhance end-users' awareness and trust in the company's innovative drugs, lay a solid foundation for accelerating their broader clinical adoption, propel Akeso's commercialization of innovative drugs into a phase of sustained, rapid, and high-quality development, and strengthen the groundwork for the company's deepened global expansion.","length":1483,"tagName":"p"},{"type":"text","content":"Akeso remains patient-centric and clinical value-driven, committed t...